SYF9aa1f014d0674f7e916aa72a8ec5c294

RecruitingPhase 2

Tau PET imaging in cognitively normal elderly subjects: A tw...

Amsterdam UMC StichtingSource

Compare

Study Type

interventional

Reported enrollment (type unavailable)

N/A

Locations

1 country

Sites

1

Brief Summary

The main objectives are to 1) investigate the relation between tau and amyloid accumulation in cognitively normal individuals, 2) test the contribution of genetic and non‐genetic factors on (longitudinal) tau accumulation in twins, and 3) test the relation of (longitudinal) tau accumulation with other AD‐markers collected in the PreclinAD study.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: recruiting
Reported enrollment (type unavailable): Not reported
Study completion date: Not reported
Date not reported
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

First Submitted
November 14, 2024
Actual (reported)

Conditions

Healthy controls (investigating preclinical Alzheimer's Disease)

Outcome Measures

Primary Outcomes (1)

1. To investigate the effect of amyloid status(positive versus negative) on (longitudinal) [18F]AV‐ 1451 accumulation in cognitively normal individuals. 2. To investigate the contribution of genetic factors and non‐genetic factors to (longitudinal) tau accumulation and its interaction with amyloid accumulation

Interventions

FlortaucipirType not reported

Eligibility Criteria

Sexall

Healthy VolunteersYes

Age GroupsOlder Adult (65+)

You may qualify if:

In order to be eligible for participation in this study, a subject must be older than 60 years, have received an [18F]flutemetamol amyloid PET scan and/or have a known amyloid status obtained from CSF.

You may not qualify if:

Sponsors & Collaborators

Amsterdam UMC Stichting
Otherlead

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Study Sites (1)

Amsterdam UMC Stichting

Amsterdam, 1081 HV, Netherlands

Anouk den Braber0031623048053 ctis@amsterdamumc.nl

Central Study Contacts

Anouk den Braber

0031623048053 a.denbraber@amsterdamumc.nl

Study Design

Study Type: interventional
Phase: phase 2

Study Record Dates

First Submitted

November 14, 2024

Source record

Download the complete CTIS (EMA) record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: European Medicines Agency (EMA), Clinical Trials Information System (CTIS). Original record and public documents are available on CTIS.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: 2024-517634-17-01
Data provider: European Medicines Agency (EMA)
Normalization version: ctis-v1

Open registry record

Source retrieved: 2026-10-31 05:44:29 UTC

Documents

D1_Protocol_2024-517634-17-01

Phase 2/3Recruiting

NCT04150198

MECHANISMS OF NEURONAL RESILIENCE IN ALZHEIMER'S DISEASE AND ITS FOCAL VARIANTS: A PET/MR STUDY

Not ApplicableRecruiting

A potential subject who meets any of the following criteria will be excluded from participation in this study if he or she: 1. Has contra indications for MRI scanning and therefore has not received brain MRI; 2. Has evidence of structural abnormalities such as major stroke or mass on MRI that is likely to interfere with interpretation of PET scan; Tau PET imaging in cognitively normal elderly subjects: A twin approach Version number 9, date: 28‐05‐2024 17 3. Has a relevant history of severe drug allergy or hypersensitivity. Relevant severe drug allergies should be determined by the Principal Investigator or Co‐Principal Investigator, and any questions about a subject’s eligibility can be directed to Avid Radiopharmaceuticals Inc.; 4. Has ever participated in an experimental study with a tau agent, unless it can be documented that the subject received only placebo during the course of the trial; 5. Has been injected with a previously administered radiopharmaceutical within 6 terminal half‐ lives or when total yearly radiation exposure exceeds 16.1 mSv for female and 22.4 mSv for male participants[26]. 6. Has a history of severe traumatic brain injury (TBI)

Contact the study team to confirm eligibility.

Blank document

L1_SIS and ICF_TauTwin

Locations

NL(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

Conditions

Outcome Measures

Primary Outcomes (1)

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

Central Study Contacts

Study Design

Study Record Dates

Source record

Documents

Locations